Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Considers National Registry For Silicone Breast Implants

This article was originally published in The Gray Sheet

Executive Summary

Due to lower-than-expected follow-up rates for Allergan and Johnson & Johnson/Mentor’s silicone-gel-filled breast implant post-approval studies, FDA advisory panel members last week called for a national registry to better document long-term outcomes and complications.

You may also be interested in...



Breast Implant Makers Can Use Registries To Fulfill Post-Market Surveillance Duties

After years of struggling to track breast implant patients with post-market surveillance surveys, silicone gel breast implant makers will be allowed by FDA to substitute data from two new registries to fulfill their duties on post-approval studies and device tracking, an FDA epidemiologist said recently.

Ideal Implant Aims For Saline Breast Implant With Natural-Tissue Feel

Start-up firm Ideal Implant aims to compete in the lucrative breast implant market with a novel design offering the safety of saline and the natural feel of silicone gel, according to founder and president Robert Hamas.

Ideal Implant Aims For Saline Breast Implant With Natural-Tissue Feel

Start-up firm Ideal Implant aims to compete in the lucrative breast implant market with a novel design offering the safety of saline and the natural feel of silicone gel, according to founder and president Robert Hamas.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel